SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Trochimiuk Janetta

(Last)

(First)

(Middle)

C/O PDS BIOTECHNOLOGY CORP

303A COLLEGE ROAD EAST

(Street)

PRINCETON

NEW JERSEY

08540

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/12/2026

3. Issuer Name and Ticker or Trading Symbol
PDS Biotechnology Corp [ PDSB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Principal Accounting Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,124	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	01/12/2036	Common Stock	70,000	$0.98	D
Stock Option (Right to Buy)	⁽²⁾	06/12/2035	Common Stock	30,000	$1.79	D
Stock Option (Right to Buy)	⁽³⁾	02/28/2034	Common Stock	30,000	$5.87	D
Stock Option (Right to Buy)	⁽⁴⁾	01/04/2033	Common Stock	25,000	$11.61	D
Stock Option (Right to Buy)	⁽⁵⁾	01/19/2032	Common Stock	31,117	$6.28	D
Stock Option (Right to Buy)	⁽⁵⁾	06/17/2031	Common Stock	27,750	$2.43	D
Stock Option (Right to Buy)	⁽⁵⁾	06/23/2030	Common Stock	5,000	$1.45	D
Stock Option (Right to Buy)	⁽⁵⁾	12/09/2029	Common Stock	10,000	$2.88	D

Explanation of Responses:

1. The option was granted on January 12, 2026, with 25% vesting on January 12, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

2. The option was granted on June 12, 2025, with 25% vesting on June 12, 2026 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

3. The option was granted on February 28, 2024, with 25% vesting on February 28, 2025 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

4. The option was granted on January 4, 2023, with 25% vesting on January 4, 2024 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

5. The options are fully vested and exercisable.

	By: /s/ Janetta Trochimiuk	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)